Beta
Back to NVO.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
eps-diluted-chart

NVO EPS Diluted

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for NVO's EPS Diluted in Q4'25 stands at 6.04 USD, reflecting a modest quarter-over-quarter increase from 4.5 USD in Q3'25 but a slight year-over-year decline of 4.7%. This value indicates continued profitability in the pharmaceutical sector, though tempered by recent growth challenges. Over the period from Q1'23 to Q4'25, EPS Diluted has shown an overall upward trend, rising from 4.39 USD to a peak of 6.53 USD in Q1'25 before stabilizing around 6 USD in the latter half of 2025. Year-over-year growth was robust in 2023, averaging 52% with consistent gains across quarters, but moderated significantly in 2024 (peaking at 29% in Q4) and turned negative in Q3'25 (-26%) and Q4'25 (-5%), highlighting potential volatility from market or operational factors. The bar chart visualization underscores quarterly fluctuations, with notable highs in Q3'24 (6.12 USD) and Q1'25, suggesting resilience amid decelerating growth momentum.